An allogeneic stem cell transplant is a procedure in which healthy blood-forming stem cells from a donor are infused into a patient to replace diseased or damaged bone marrow. It differs from an autologous transplant, where your own stem cells are collected and returned to you. The word “allogeneic” simply means the cells come from another person. This type of transplant is most commonly used to treat blood cancers and other serious blood disorders, and it carries a unique advantage: the donor’s immune cells can recognize and attack remaining cancer cells in ways your own immune system could not.
How It Works
Your bone marrow is the factory inside your bones that produces red blood cells, white blood cells, and platelets. When diseases like leukemia corrupt that factory, an allogeneic transplant essentially replaces it. Healthy stem cells from a donor are delivered through an IV line, similar to a blood transfusion. Those cells travel through your bloodstream, settle into your bone marrow, and begin producing new, healthy blood cells.
One of the most important features of this transplant is something called the graft-versus-tumor effect. Because the donor’s immune cells are genetically different from yours, they can detect leftover cancer cells that your own immune system might overlook. The donated cells treat those cancer cells as foreign invaders and attack them. This built-in immune response against cancer is a major reason allogeneic transplants are chosen over autologous ones for certain diseases, since your own stem cells could potentially be contaminated with cancer cells.
Conditions It Treats
Allogeneic transplants are used primarily for cancers and disorders of the blood and bone marrow. The strongest evidence supports its use in acute myeloid leukemia (AML) with high-risk features or disease that has returned after initial treatment, advanced chronic myeloid leukemia (CML) or CML that hasn’t responded to targeted therapy, myelodysplastic syndromes (MDS) with a high risk of progressing to leukemia, and certain other bone marrow disorders like myelofibrosis. It is also used for acute lymphoblastic leukemia (ALL), some lymphomas, and non-cancerous conditions like severe aplastic anemia or sickle cell disease where the bone marrow needs to be replaced entirely.
Finding a Matching Donor
The success of an allogeneic transplant depends heavily on how well the donor’s tissue type matches yours. This matching is based on proteins called human leukocyte antigens (HLA), which sit on the surface of your cells and help your immune system distinguish “self” from “foreign.” The closer the HLA match, the lower the risk that the donated cells will aggressively attack your body.
Doctors typically test for matches at four key HLA markers (called HLA-A, B, C, and DRB1), looking for a perfect “8 out of 8” match. Sometimes matching is extended to include additional markers for a “10 out of 10” match. There are several types of donors:
- Matched sibling donor: A brother or sister who shares the same HLA type. This is often the ideal match, but only 13% to 51% of patients have one available, depending on family size and ethnic background.
- Matched unrelated donor: A volunteer found through a bone marrow registry. Availability ranges from 29% to 78%, with patients from common ethnic backgrounds having better odds.
- Haploidentical donor: A half-matched family member, such as a parent or child, who shares only about half your HLA markers. Advances in transplant techniques have made this a much safer option than it once was, dramatically expanding the pool of eligible donors.
- Umbilical cord blood: Stem cells collected from a newborn’s umbilical cord and stored in a cord blood bank. These require a less stringent match (a minimum 4 out of 6) but contain fewer cells, which can slow recovery.
Where the Stem Cells Come From
Donor stem cells can be collected from three sources: peripheral blood, bone marrow, or umbilical cord blood. Each has trade-offs that influence which one your medical team recommends.
Peripheral blood stem cells are the most commonly used source today. The donor receives injections for several days beforehand that push stem cells out of the bone marrow and into the bloodstream, where they’re collected through a process similar to donating blood. Peripheral blood contains a much higher concentration of stem cells and leads to faster engraftment, with new blood cell production typically beginning around day 12 after transplant. The downside is a higher rate of chronic graft-versus-host disease, occurring in about 53% of recipients at two years compared to 41% with bone marrow.
Bone marrow is collected directly from the donor’s hip bones under anesthesia. It produces slower engraftment (around day 15) but carries a lower risk of chronic graft-versus-host disease. It also has a higher rate of graft failure, about 9% compared to 3% with peripheral blood. Bone marrow may be recommended for patients whose immune systems are already suppressed from prior chemotherapy, since they face a lower risk of rejecting the graft and can benefit from the reduced long-term complications.
Cord blood is the slowest to engraft, with a median of 23 to 25 days to produce adequate white blood cells. It is typically reserved for patients who lack a well-matched adult donor.
The Conditioning Phase
Before you receive donor cells, your body needs preparation through a phase called conditioning. This involves chemotherapy, sometimes combined with total body irradiation, and it serves two purposes: destroying as many cancer cells as possible and suppressing your immune system enough that it won’t reject the incoming donor cells.
There are three intensities of conditioning. Myeloablative conditioning is the most aggressive. It completely wipes out your bone marrow’s ability to produce blood cells, meaning you cannot survive without the transplant afterward. This approach gives the strongest anti-cancer effect but causes the most severe side effects, including significant drops in all blood cell counts, mouth sores, and potential organ damage.
Reduced-intensity conditioning uses lower doses that still cause significant immune suppression but are less toxic. Your bone marrow could theoretically recover on its own, though slowly. Non-myeloablative conditioning is the gentlest approach, causing only mild suppression of blood cell production. Both of these lighter regimens rely more heavily on the donor’s immune cells to fight the cancer (the graft-versus-tumor effect) rather than on the chemotherapy itself. They were developed to make transplants accessible to older patients and those with other health conditions who could not tolerate the full-intensity approach.
The Transplant Day and Engraftment
The transplant itself is anticlimactic compared to the preparation. Donor stem cells are infused through a central IV line, much like receiving a blood transfusion. The cells are either dripped in by gravity or gently pushed through a syringe. There is no surgery involved.
After infusion, the waiting period begins. The transplanted stem cells need time to migrate to your bone marrow, settle in, and start producing new blood cells. This process is called engraftment. Doctors confirm it has occurred when your neutrophil count (a type of white blood cell critical for fighting infection) stays above a threshold level for three consecutive days. With peripheral blood stem cells, this typically happens around day 12. With bone marrow, it’s closer to day 15. Cord blood takes the longest, averaging 23 to 25 days.
Platelet recovery follows a similar pattern but takes a few days longer. Patients receiving peripheral blood stem cells usually reach adequate platelet levels by day 15, while bone marrow recipients reach that milestone around day 20. Until engraftment occurs, you are extremely vulnerable to infection and bleeding, which is why this period is spent in the hospital under close monitoring.
Graft-Versus-Host Disease
The most significant complication of allogeneic transplant is graft-versus-host disease (GvHD). The same donor immune cells that can attack your cancer can also attack your healthy tissues. If the donor’s HLA markers differ enough from yours, the new immune cells may see your body’s normal cells as threats.
Acute GvHD typically appears within the first 100 days after transplant, though it can develop later. It most commonly targets the skin (rashes), the digestive tract (nausea, diarrhea, abdominal pain), and the liver. Chronic GvHD can appear any time after the transplant but most cases start within two years. It can affect a wider range of organs, including the skin, mouth, liver, lungs, digestive tract, muscles, joints, and genitals. Chronic GvHD can resemble autoimmune conditions, with symptoms like dry eyes, dry mouth, skin tightening, and shortness of breath.
To prevent GvHD, you’ll take immunosuppressive medications starting before or around the time of transplant. These drugs intentionally dial down the new immune system’s activity. Over time, as the donor immune cells learn to coexist with your body, doctors gradually reduce these medications. The tapering process is slow and carefully monitored, often taking many months. If signs of GvHD appear during tapering, the medication dose is increased back to the previous level.
Life After Transplant
Recovery from an allogeneic transplant is measured in months and years, not weeks. The initial hospital stay typically lasts several weeks, covering the conditioning phase through early engraftment. After discharge, frequent outpatient visits continue for months to monitor blood counts, watch for GvHD, and manage medications.
Your rebuilt immune system takes a long time to fully mature. For the first several months, you remain at elevated risk for infections that a healthy immune system would easily handle. Vaccinations you received earlier in life no longer protect you, and you’ll eventually need to be re-vaccinated on a schedule your care team provides. Many patients can return to normal activities within 6 to 12 months, though some effects of chronic GvHD or the conditioning regimen can linger longer. Regular follow-up continues for years to monitor for late effects, disease relapse, and the gradual recovery of immune function.